Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have
relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by
blocking the enzymes necessary for their growth.